Midazolam (BUCCOLAM®) is recommended as an option for use within NHS Wales for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to ...
Clinicians and carers of children and adolescents suffering from prolonged, acute, convulsive seizures now have access to Buccolam® (midazolam oromucosal solution), a newly approved rescue medication ...
ViroPharma Inc. ( VPHM) recently announced that the Scottish regulatory body has approved its epilepsy drug, Buccolam to be used as a treatment for prolonged, acute, convulsive seizures in infants, ...
Buccolam is oral midazolam provided in a pre-measured, age-specific dose formulation for convenient buccal (i.e. via the cavity between the cheek and gum line) delivery. Buccal midazolam has been ...
ViroPharma Inc. launched its epilepsy drug Buccolam this week in the United Kingdom. ViroPharma Inc. launched its epilepsy drug Buccolam this week in the United Kingdom. The Exton, Pa., ...
Paves way for the extension of well-established and pan-European market-leading brand to include the treatment of adult patients Buccolam ® is a prescription brand buccal midazolam indicated for the ...